B Vitamins (Folic Acid, B6, B12) and Cataracts — What a Large Trial in Women Showed

A cataract (Latin: cataracta) is progressive clouding of the eye's lens — the structure responsible for focusing light onto the retina. As we age, the proteins that make up the lens gradually lose their transparency, which shows up as blurred, hazy-looking vision, worse night vision, increased sensitivity to glare, and gradual fading of colors. It's one of the most common causes of age-related vision decline — affecting a large proportion of people over 65 to some degree.

The good news is that cataracts have very effective treatment today: surgical removal of the clouded lens and replacement with an artificial intraocular lens. It's one of the most commonly performed and safest procedures in all of medicine, with a very high success rate for restoring visual acuity. Cataracts are therefore not a disease that must be fended off at all costs to avoid irreversible blindness — rather, it's a condition that can be effectively treated given surgical intervention at the right moment.

Even so, there has long been a search for ways to slow or delay cataract development through non-surgical means, including supplementation. Folic acid, vitamin B6, and vitamin B12 made the list of candidates for two reasons. First, in the eye's lens, as in other tissues, oxidative processes are considered one of the mechanisms accelerating clouding, and B vitamins participate indirectly in metabolic processes related to protecting cells from oxidative stress. Second, these three vitamins together lower blood homocysteine levels, and elevated homocysteine has been linked in observational studies, among other things, to poorer condition of the blood vessels supplying the eye's tissues. These were, however, hypotheses based on mechanism and observational data — not hard evidence from interventional trials, which is worth keeping in mind before we move on to the results.

The answer to whether this hypothesis holds up in practice came from a study by William G. Christen's team, published in the journal Ophthalmic Epidemiology in 2016. It was a secondary study, conducted within a larger, well-known research project (the Women's Antioxidant and Folic Acid Cardiovascular Study) involving women with cardiovascular disease or multiple risk factors for it — a population in which lowering homocysteine was originally being tested for cardiovascular benefit, with the assessment of cataract impact serving as an additional, pre-planned study goal.

It's worth pausing on exactly what these two results mean, because they differ not only in their numbers but in their evidentiary weight. The primary outcome (cataract incidence itself) was the main, pre-planned question of the study — and the answer to it is unambiguous: no, these vitamins did not reduce the risk of developing cataracts. The secondary outcome (need for surgery) was an additional endpoint, but it's the one that turned out to be surprising — and in an unfavorable direction.

Why would supplementation increase the risk of needing surgery if it didn't significantly increase cataract incidence itself? The study authors didn't offer a definitive mechanism — this is an empirical observation, not a fully explained cause-and-effect relationship. Possible explanations include that in women taking the vitamins, cataracts may have progressed faster to a stage requiring surgical intervention, even though the overall frequency of cataract diagnosis didn't differ significantly between groups. This distinction — between "developing a cataract" and "needing cataract surgery" — is subtle but clinically meaningful, since it's precisely the surgery, and the moment it becomes necessary, that matters most to the patient.

There's an important rule in clinical trial methodology: secondary outcomes (endpoints other than the main, pre-planned goal of the study) should be interpreted with a bit more caution than the primary outcome. The reason is statistical — the more comparisons and analyses conducted within a single study, the greater the chance that one of the results reaches statistical significance by chance rather than due to a real effect (the so-called multiple comparisons problem). This is a real, methodologically justified rule of caution worth keeping in mind.

At the same time, that same caution shouldn't turn into automatically dismissing an inconvenient result. A hazard ratio of 1.28 with a confidence interval of 1.01-1.63 and a p-value of 0.04, obtained in a study of nearly 4,000 participants followed for an average of 7.3 years, is not a borderline result stemming from a small sample or a short observation period — it's a large, long-term study in which such a signal appeared despite solid statistical power. The confidence interval does only narrowly clear the 1.0 threshold (lower bound 1.01), meaning the result is at the edge of statistical significance, but it is still a statistically significant increase in risk, not merely a trend or tendency.

It's worth emphasizing that this study didn't test a single vitamin in isolation, but a specific combination of three B vitamins at specific, fairly high doses (folic acid 2.5 mg, B6 50 mg, B12 1 mg daily — well above typical doses in standard multivitamins). The results therefore apply to this specific combination and dose, not to every possible form of B-vitamin supplementation in any amount. That doesn't automatically mean every other dose or form would have an identical effect — but it does mean that the hypothesis "B vitamins that lower homocysteine protect against cataracts," tested in this well-designed form, was not confirmed, and in the process revealed a concerning signal in the opposite direction.

This is an important general lesson that goes beyond cataracts: lowering a biomarker observationally associated with a disease (in this case, homocysteine) doesn't guarantee that an intervention lowering that biomarker will actually prevent the disease. Associations seen in observational studies (people with higher homocysteine more often have eye problems) don't always translate into the effectiveness of an intervention that lowers that homocysteine — a classic "correlation isn't causation" trap that recurs repeatedly in supplement medicine.

This study had certain limitations worth keeping in mind. Participants were exclusively women aged 40 and older with cardiovascular disease or its risk factors — the results don't necessarily transfer directly to men or to people without cardiovascular burden. The study assessed one specific combination of three vitamins at specific doses, not every possible form of B-vitamin supplementation. The cataract surgery result was a secondary outcome, which, as described above, justifies some additional interpretive caution, though it doesn't invalidate it as a signal worth attention. Finally, the mechanism linking supplementation to increased surgery risk wasn't fully explained, leaving room for further studies to verify this result in other populations.

This is one of those rare cases in the supplement literature where a large, well-designed study not only fails to confirm an expected benefit, but reveals a potential signal of harm — and a signal solid enough methodologically (large sample, long follow-up, randomization, blinding) that it deserves to be taken seriously, even though it concerns a secondary endpoint. The honest summary is: there is no evidence of benefit, and there is a credible, though mechanistically uncertain, signal of possible harm.